DDrare: Database of Drug Development for Rare Diseases

Searched query = "Fibrodysplasia ossificans progressiva", "FOP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AZD0530; AZD0530 Difumarate; Garetosmab; PALOVAROTENE; PALOVAROTENE - 1.5mg; PALOVAROTENE - 10 mg; PALOVAROTENE - 1mg; PALOVAROTENE - 2 mg; PALOVAROTENE - 2.5 mg; PALOVAROTENE - 3 mg; PALOVAROTENE - 4 mg; PALOVAROTENE - 5 mg; Palovarotene; Palovarotene dose level 1; Palovarotene dose level 2; Palovarotene dose level 3; Palovarotene dose level 4; Perhexiline; REGN2477; SARACATINIB DIFUMARATE; Saracatinib

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02979769 (ClinicalTrials.gov)	November 28, 2016	23/11/2016	An Open-Label Extension Study of Palovarotene to Prevent Heterotopic Ossification in FOP Subjects in France	A Phase 2, Open-Label Extension, Efficacy and Safety Study of a RAR?-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)	Fibrodysplasia Ossificans Progressiva	Drug: Palovarotene dose level 1;Drug: Palovarotene dose level 2	Clementia Pharmaceuticals Inc.	NULL	Active, not recruiting	6 Years	65 Years	All	9	Phase 2	France
2	NCT02279095 (ClinicalTrials.gov)	October 27, 2014	26/10/2014	An Open-Label Extension Study of Palovarotene Treatment in FOP	A Phase 2, Open-Label Extension, Efficacy and Safety Study of a RAR? Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)	Fibrodysplasia Ossificans Progressiva	Drug: Palovarotene dose level 1;Drug: Palovarotene dose level 2;Drug: Palovarotene dose level 3;Drug: Palovarotene dose level 4	Clementia Pharmaceuticals Inc.	NULL	Active, not recruiting	6 Years	65 Years	All	54	Phase 2	United States;Argentina;Australia;France;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02979769
(ClinicalTrials.gov)

November 28, 2016

23/11/2016

An Open-Label Extension Study of Palovarotene to Prevent Heterotopic Ossification in FOP Subjects in France

A Phase 2, Open-Label Extension, Efficacy and Safety Study of a RAR?-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)

Fibrodysplasia Ossificans Progressiva

Drug: Palovarotene dose level 1;Drug: Palovarotene dose level 2

Clementia Pharmaceuticals Inc.

NULL

Active, not recruiting

6 Years

65 Years

All

Phase 2

France

NCT02279095
(ClinicalTrials.gov)

October 27, 2014

26/10/2014

An Open-Label Extension Study of Palovarotene Treatment in FOP

A Phase 2, Open-Label Extension, Efficacy and Safety Study of a RAR? Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)